Related Experiment Video

Updated: Sep 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of

Xue Kong1, Ken H Young1

  • 1Duke University School of Medicine, Duke Cancer Center, Durham, NC 27710, USA.

Blood Science (Baltimore, Md.)
|July 4, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

Related Experiment Videos

Last Updated: Sep 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

A dual-barrier disruption strategy employing lufenuron/dsRNA nanocomplexes overcomes both cuticular and intestinal barriers in late-instar lepidopteran pests.

Pesticide biochemistry and physiology·2026

Anomalies of Net Primary Productivity under Compound Marine Heatwaves and Microplastics.

Environmental science & technology·2026

In vitro susceptibility and provisional epidemiological cutoff values for eight antifungal agents against Trichophyton mentagrophytes and Trichophyton interdigitale: a multicenter study from China.

Journal of clinical microbiology·2026

Detection of Trichophyton indotineae using a species-specific genomic marker: a marker identification and assay validation study.

The Lancet. Microbe·2026

Fear-related psychological experiences in people with Parkinson's disease: a systematic review of qualitative studies.

BMC psychology·2026

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026

Thiolutin alleviates acute graft-versus-host disease (aGVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation.

Blood science (Baltimore, Md.)·2026

LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML.

Blood science (Baltimore, Md.)·2026

Platelet subpopulations and contribution to hemostasis.

Blood science (Baltimore, Md.)·2026

Development and validation of a deep learning model to predict heparin response in critically ill patients with deep vein thrombosis receiving continuous intravenous heparin infusion.

Blood science (Baltimore, Md.)·2026

Tgfbr3 is required for the long-term maintenance of self-renewal potential in murine hematopoietic stem cells.

Blood science (Baltimore, Md.)·2026

Characterizing and mitigating cross-library PCR chimeras in Perturb-seq using Perturb-Audit.

Blood science (Baltimore, Md.)·2026

Are Urooncologists Onboard?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

The State of the Art of Theranostics and Its Future.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

[Alzheimer's disease: scientific advances, diagnostic challenges and therapeutic perspectives].

Soins; la revue de reference infirmiere·2026

Photobiomodulation therapy and the regulation of excitation-inhibition balance in neurological and psychiatric disorders: Mechanistic and translational perspectives.

Neuroscience·2026

Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis.

PharmacoEconomics - open·2026

MiR-590-3p Targets HMGB1 to Alleviate Endothelial Injury Induced by β2GPI/Anti-β2GPI Immune Complex.

International journal of immunogenetics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us